Fig. 4From: Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis CEfficacy of daclatasvir plus asunaprevir combination therapy for chronic hepatitis C genotype 1b: virologic response in total patients (a), comparison of virologic response based on liver cirrhosis (LC, b) and previous treatment experience (c)Back to article page